Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Randomized, Double-Blinded Study to Assess the Safety, Reactogenicity and Immunogenicity of JCXH-108, an mRNA-based Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Healthy Subjects ≥ 60 Years of Age and 18-45 Years of Age

NCT06564194 is registered in ClinicalTrials.gov with Immorna Biotherapeutics, Inc. as lead sponsor.

NCT NCT06564194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06564194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Randomized, Double-Blinded Study to Assess the Safety, Reactogenicity and Immunogenicity of JCXH-108, an mRNA-based Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Healthy Subjects ≥ 60 Years of Age and 18-45 Years of Age
Lead sponsor
Immorna Biotherapeutics, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 25, 2024
Completion date
June 30, 2026
Enrollment
75 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

infectious disease, respiratory syncytial virus (rsv)